These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17418516)

  • 41. Efficacy of Lorenzo oil in adrenomyeloneuropathy.
    Simon E
    Ann Neurol; 1994 Jul; 36(1):116-7. PubMed ID: 8024253
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of glycerol trioleate oil milk formula administration on very long chain fatty acid levels and clinical course in a patient with Zellweger syndrome.
    Tylki-Szymańska A; Stradomska TJ
    Eur J Pediatr; 1995 Oct; 154(10):867. PubMed ID: 8529694
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of generalized peroxisomal disorders with docosahexaenoic acid ethyl ether].
    Martínez M; Vázquez E; García-Silva MT; Beltrán JM; Castelló F; Pineda M; Mougan I
    Rev Neurol; 1999 Jan; 28 Suppl 1():S59-64. PubMed ID: 10778491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dietary docosahexaenoic acid but not arachidonic acid influences central nervous system fatty acid status in baboon neonates.
    Hsieh AT; Brenna JT
    Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):105-10. PubMed ID: 19524425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders.
    Martínez M; Vázquez E; García-Silva MT; Manzanares J; Bertran JM; Castelló F; Mougan I
    Am J Clin Nutr; 2000 Jan; 71(1 Suppl):376S-85S. PubMed ID: 10618001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic developments in peroxisome biogenesis disorders.
    McGuinness MC; Wei H; Smith KD
    Expert Opin Investig Drugs; 2000 Sep; 9(9):1985-92. PubMed ID: 11060787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
    Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
    J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of long-chain polyunsaturated fatty acids in the first year of life.
    Agostoni C
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47 Suppl 2():S41-4. PubMed ID: 18931599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy.
    Maeda K; Suzuki Y; Yajima S; Asano J; Yamaguchi S; Matsumoto N; Borel J; Moser HW; Orii T
    Brain Dev; 1992 Nov; 14(6):409-12. PubMed ID: 1492654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does dietary DHA improve neural function in children? Observations in phenylketonuria.
    Koletzko B; Beblo S; Demmelmair H; Müller-Felber W; Hanebutt FL
    Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):159-64. PubMed ID: 19615874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo's oil.
    Sedlmayr P; Plecko B; Paschke E; Zenz W; Ramschak H; Toplak H; Wascher TC; Wilders-Truschnig M; Stöckler S
    J Inherit Metab Dis; 1995; 18(1):101-2. PubMed ID: 7623436
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapy of X-linked adrenoleukodystrophy.
    Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
    Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids.
    Kidd PM
    Altern Med Rev; 2007 Sep; 12(3):207-27. PubMed ID: 18072818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil.
    Moser HW; Powers JM; Smith KD
    Brain Pathol; 1995 Jul; 5(3):259-66. PubMed ID: 8520725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.
    Pour RB; Stöckler-Ipsiroglu S; Hunneman DH; Gahr M; Korenke GC; Pabst W; Hanefeld F; Peters A
    J Inherit Metab Dis; 2000 Mar; 23(2):113-9. PubMed ID: 10801052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapy of X-linked adrenoleukodystrophy.
    Moser HW
    NeuroRx; 2006 Apr; 3(2):246-53. PubMed ID: 16554262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A happier sequel to Lorenzo's Oil?
    Wanders RJ
    Nat Med; 1998 Nov; 4(11):1245-6. PubMed ID: 9809546
    [No Abstract]   [Full Text] [Related]  

  • 58. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
    Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
    Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formula supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA): a critical review of the research.
    Wright K; Coverston C; Tiedeman M; Abegglen JA
    J Spec Pediatr Nurs; 2006 Apr; 11(2):100-12; discussion 112-3. PubMed ID: 16635189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial.
    Smithers LG; Gibson RA; McPhee A; Makrides M
    Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):141-6. PubMed ID: 18951004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.